Under the agreement, Theradiag will promote, license, and distribute PredictImmune's PredictSure IBD test in France, Belgium, Luxembourg, Switzerland, and the Maghreb countries.
The Australia-based firm intends to raise funds in two tranches and use the capital to expand in the US and the UK.
The PCR-based test analyzes mitochondrial DNA to detect prostate cancer in advance of biopsy, independent of prostate-specific antigen levels and age.
The company delivered organic growth across its four business segments and raised its revenue and earnings guidance for the year.
The firm saw 26 percent growth in molecular biology sales, driven in part by 25 percent sales growth for the BioFire FilmArray product line.
Under the deal, KSL will commercialize and facilitate orders of the PredictSURE IBD test throughout North America and will also process all samples through its laboratory, KSL Diagnostics.
The test is the latest in a series of CE-IVD-marked assays the company has launched for use on Becton Dickinson's PCR-based BD Max platform.
The validation of its current CLIA testing comes as Biocept is in the early stages of expanding to provide kit versions of its liquid biopsy tests.
The agreement enables NeuMoDx to bring sample-to-result HPV screening to customers in Europe, where its systems are distributed by Qiagen.
The firm said that its newly CE-marked test for intestinal infections is suitable for use in laboratories and hospitals, and provides results in 90 minutes.
UgenTec's FastFinder software platform uses artificial intelligence to enable analysis and interpretation of qPCR data, workflow automation, and genotyping.
The in vitro diagnostic test can deliver molecular results from whole blood samples in less than three hours, the company said.
The FDA clearance follows earlier US marketing approval for the firm's C. Difficile assay.
The firm will use the funds to continue expanding its technology into food and agriculture testing, in addition to growing its cannabis testing business.
The director of the Biomedical Advanced Research and Development Authority has launched two new funding programs in the past three years.
CareDx claims that Eurofins Viracor infringes on its patent related to noninvasive monitoring of organ transplant rejection through cell-free DNA analysis.
The Simplexa VZV Swab Direct runs on the firm's Liason MDX instrument and has also been submitted to the US Food and Drug Administration.
The distributor, Bionuclear Puerto Rico, will give T2 access to approximately 64 hospitals in Puerto Rico and the US Virgin Islands.
The pilot study with the Mayo Clinic is the final step before SkylineDx commences a US trial next year for its molecular test for primary cutaneous melanoma.
The assay is based on the company's AmpiProbe technology, which uses fluorescent reporter-labeled primers and quencher-labeled primers to amplify DNA.
Google's Project Nightingale has collected health information on millions of Americans, according to the Wall Street Journal.
An opinion piece at The Hill criticizes the proposed plan to collect DNA samples from migrants at the US border.
Nature News writes that women in chemistry are less likely to have their manuscripts accepted for publication.
In PNAS this week: tRNA fragment signature for chronic lymphocytic leukemia, genomic sites sensitive to ultraviolet radiation in melanocytes, and more.